Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy.
Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy.
summit therapeutics宣布Ivonescimab联合化疗在中国获得了营销授权，该公司股票价格上涨。
Summit Therapeutics Shares Are Trading Higher After the Company Announced That It Received Marketing Authorization in China for Ivonescimab in Combination With Chemotherapy. Also, the Company Announced That It Accepted an Unsolicited Offer From an Institutional Investor to Purchase 22,222,222 Shares of Stock at $9.00 per Share and Will Use the Net Proceeds to Advance Clinical Development of Ivonescimab.
Summit Therapeutics的股票价格在公司宣布其Ivonescimab联合化疗获得中国营销授权后上涨。此外，该公司宣布接受了一家机构投资者以9美元/股的价格购买22222222股股票的非要约收购，并将使用净收益推进Ivonescimab的临床发展。